期刊
CANCER RESEARCH
卷 81, 期 23, 页码 5803-5805出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-21-3548
关键词
-
类别
资金
- National Health and Medical Research Council (NHMRC) of Australia
- National Breast Cancer Foundation
- Cancer Council of Victoria
- Cancer Research Irvington postdoctoral fellowship [3530]
- Victorian Cancer Agency [MCRF20011]
- NHMRC Senior Research Fellowship [APP1136680]
Cancer immunotherapy has shown unprecedented clinical responses in patients with cancer, but some cancers remain refractory to these therapies. Combining adoptive T-cell therapy with checkpoint inhibition has become an innovative approach to overcome resistance in cancer treatment.
Cancer immunotherapy utilizing checkpoint blockade antibodies or adoptive cellular therapy (ACT) with tumor-specific T cells has led to unprecedented clinical responses in patients with cancer and has been considered one of the most significant breakthroughs in cancer treatment in the past decade. Nevertheless, many cancers remain refractory to these therapies due to the presence of an immunosuppressive tumor microenvironment. This has led to the innovative idea of combining ACT with checkpoint inhibition. A landmark 2004 study by Blank and colleagues published in Cancer Research was one of the original demonstrations that adoptive transfer of T cells lacking the negative T-cell regulator, PD-1, was able to restore functional T-cell antitumor activity, resulting in rapid regression of established tumors in a preclinical model. This work was instrumental in not only driving clinical studies utilizing checkpoint inhibition but also a new wave of recent trials involving checkpoint blockade in the setting of ACT.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据